JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

The Role of Artificial Intelligence in Diagnosis, Therapy, and Drug Development for Cancer

Narayana Raju P[1], Leela Sri Suchithra Kumari Borusu*[2], Bhaskara Raju V[3]

[1] *Professor, Department of Pharmaceutics, Sri Vasavi Institute of Pharmaceutical Sciences, Tadepalligudem, Andhra Pradesh, India*
[2] *UG Scholar, Department of Pharmaceutics, Sri Vasavi Institute of Pharmaceutical Sciences, Tadepalligudem, Andhra Pradesh, India*
[3] *Principal, Department of Pharmaceutics, Sri Vasavi Institute of Pharmaceutical Sciences, Tadepalligudem, Andhra Pradesh, India*

Publication history: Received on 18th October 2025; Revised on 2nd November 2025; Accepted on 7th November 2025

Article DOI: 10.69613/vjp1x894

Abstract: The integration of Artificial Intelligence (AI) into oncology signifies a paradigm shift in the management of malignancies, directly addressing the complexities of cancer biology and the exponential growth of biomedical data. As a heterogeneous collection of diseases characterized by intricate genetic and epigenetic alterations, cancer necessitates advanced analytical tools for effective clinical management. Machine Learning (ML) and Deep Learning (DL) technologies are now pivotal in analyzing high-dimensional datasets derived from multi-omics, medical imaging, and electronic health records, demonstrating superior capability in identifying subtle patterns imperceptible to human analysis. These computational models are revolutionizing early detection, where radiomics and genomic sequencing significantly enhance diagnostic precision. In the therapeutic domain, AI optimizes radiotherapy planning, predicts drug sensitivity, and facilitates robotic-assisted surgery, ensuring interventions are tailored to individual patient profiles. Beyond direct clinical care, these systems improve patient management through remote monitoring and streamline clinical trial recruitment processes. Additionally, pharmaceutical innovation is accelerated by computational frameworks that expedite drug discovery and repurposing. Ultimately, the synthesis of these technologies drives the transition towards highly personalized, data-driven oncological care, provided that implementation is supported by rigorous validation and robust ethical standards.

Keywords: Artificial Intelligence; Precision Oncology; Radiomics; Genomics; Drug Development.

1. Introduction

Malignancies constitute a primary challenge to global public health, accounting for approximately one in six deaths worldwide, a statistic that underscores the urgent necessity for advanced clinical interventions [1]. According to recent global cancer statistics, the incidence and mortality rates of cancer continue to rise, presenting a formidable burden on healthcare systems globally. Cancer is not a singular pathology but a complex aggregate of distinct diseases, each defined by unique molecular profiles, histological characteristics, and clinical trajectories. While historical advancements in detection and therapeutics have improved survival rates for many cancer types, patient outcomes remain heavily contingent upon the stage of diagnosis and the biological specificity of the tumor. The traditional "one-size-fits-all" approach to treatment is increasingly being replaced by precision medicine; however, the sheer volume and complexity of data required to implement this spanning genomics, transcriptomics, proteomics, and radiomics often exceed the cognitive processing capabilities of human clinicians.

This variability and data density highlight the critical need for robust methodologies capable of facilitating early detection and optimizing therapeutic strategies through automated, high-throughput analysis. The advent of Artificial Intelligence (AI) offers a formidable mechanism to address these challenges. AI refers to the capability of computational systems to perform tasks typically requiring human intelligence, such as pattern recognition, complex decision-making, and language understanding. Within this domain, Deep Learning (DL) has emerged as a powerful tool, capable of identifying latent patterns within vast databases that exceed human analytical capacity [2]. Unlike traditional statistical methods, DL algorithms, particularly Convolutional Neural Networks (CNNs) and Recurrent Neural Networks (RNNs), can learn feature representations directly from raw data without the need for manual feature extraction.

The applicability of these technologies extends across various data modalities, including radiographic imaging (CT, MRI, PET), electronic health records (EHRs), and high-fidelity genomic sequences. Furthermore, Natural Language Processing (NLP) enables the extraction of structured data from unstructured clinical notes and pathology reports, thereby enriching the information available

* Corresponding author: Leela Sri Suchithra Kumari Borusu

for clinical decision support. AI systems enhance diagnostic accuracy, refine screening protocols, and support predictive modeling regarding disease progression by integrating these diverse data streams [3]. For instance, AI algorithms can detect subtle micro-calcifications in mammograms earlier than standard screening or predict the likelihood of metastasis based on primary tumor genetics. Consequently, these technologies are integral to the advancement of precision medicine, facilitating treatment regimens tailored to the specific genetic architecture of a patient's tumor, thereby maximizing therapeutic efficacy while mitigating adverse effects [4]. As the volume of oncological data continues to expand, the role of AI in synthesizing this information into actionable clinical insights becomes not just advantageous, but essential for the future of cancer care.

2. Artificial Intelligence in Oncology

Artificial Intelligence (AI) serves as an umbrella term for computational systems designed to emulate human cognitive functions, such as learning, reasoning, and problem-solving. Within the oncological domain, Machine Learning (ML) has emerged as the dominant subset, characterized by algorithms that iteratively improve their performance through exposure to data rather than relying on explicit, rule-based programming. These methodologies are broadly categorized based on the nature of the signal used for learning. Supervised learning remains the most prevalent approach in cancer research, where algorithms are trained on labeled datasets such as histology slides annotated with "malignant" or "benign" labels to map input variables to specific output targets. Common algorithms in this category include Support Vector Machines (SVM), which classify data by finding the optimal hyperplane separation, and Random Forests, which aggregate predictions from multiple decision trees to enhance accuracy and reduce overfitting.

Table 1. Taxonomy of Artificial Intelligence in Oncology

AI Category	Algorithms	Data Input	Applications
Supervised Learning	Support Vector Machines (SVM), Random Forests, Decision Trees	Labeled clinical datasets, annotated histology slides	Tumor classification (Malignant vs. Benign) Survival prediction based on clinical features
Unsupervised Learning	K-Means Clustering, Principal Component Analysis (PCA)	Unlabeled genomic expression data, multi-omics profiles	Discovery of novel tumor subtypes Patient stratification based on molecular signatures
Deep Learning	Convolutional Neural Networks (CNN)	Medical imaging (CT, MRI), Whole Slide Images (WSI)	Automated tumor segmentation Detection of lymph node metastasis Radiomic feature extraction
Recurrent Neural Networks (RNN)	Long Short-Term Memory (LSTM)	Sequential data (EHR time-series, genomic sequences)	Disease progression modeling Analyzing longitudinal patient records
Reinforcement Learning	Q-Learning, Deep Q-Networks	Dynamic clinical environments	Optimizing chemotherapy dosing schedules Adaptive radiotherapy planning
Natural Language Processing (NLP)	BERT, BioBERT, Named Entity Recognition (NER)	Unstructured clinical notes, pathology reports	Automated extraction of phenotypes from EHRs Clinical trial eligibility screening

Conversely, unsupervised learning algorithms operate on unlabeled data to identify inherent structures, clusters, or patterns without predefined outcomes. This approach is particularly valuable in molecular stratification, where it can reveal distinct tumor subtypes based on gene expression profiles that were previously unrecognized. A third paradigm, Reinforcement Learning (RL), is gaining traction in treatment optimization; here, an "agent" learns to make a sequence of decisions (e.g., dosage adjustments) to maximize a cumulative reward (e.g., tumor shrinkage) while interacting with a dynamic environment.

Deep Learning (DL), a specialized evolution of ML, utilizes Artificial Neural Networks (ANNs) with many layers (hence "deep") to model complex, non-linear relationships in high-dimensional data. While traditional ML often requires manual feature extraction where experts define specific attributes like tumor texture DL architectures, such as Convolutional Neural Networks (CNNs), automatically learn hierarchical feature representations directly from raw inputs like pixel data. This capability is instrumental in navigating the high-dimensionality of biomedical data [5].

Moreover, Natural Language Processing (NLP) represents a critical frontier for unlocking the vast repositories of unstructured clinical text found in Electronic Health Records (EHRs). NLP algorithms parse pathology reports, clinical notes, and discharge summaries to extract structured phenotypic data, thereby bridging the gap between clinical narratives and quantitative analysis. To

ensure these models are robust and clinically applicable, rigorous validation protocols are essential. This typically involves partitioning datasets into distinct training (for model learning), validation (for hyperparameter tuning), and testing subsets (for unbiased performance evaluation) to mitigate the risk of overfitting a phenomenon where a model memorizes the training data but fails to generalize to new, unseen patient populations



Figure 1. The AI-Integration in Cancer Treatment

3. Applications in Cancer Diagnosis

3.1. Genomic and Molecular Data Analysis

3.1.1. Genomic Sequencing and Variant Interpretation

Molecular characterization is fundamental to modern oncology, aiming to delineate the specific mutations, structural rearrangements, and gene expression alterations that drive tumorigenesis [6]. High-throughput sequencing technologies, including Whole Genome Sequencing (WGS) and Whole Exome Sequencing (WES), allow for the comprehensive identification of genetic alterations across the cancer genome [7]. A critical challenge in this field is distinguishing between "driver" mutations, which confer a survival advantage to cancer cells, and "passenger" mutations, which are biologically neutral [8]. AI algorithms are increasingly deployed to automate this differentiation, reducing the reliance on manual curation which is prone to error and variability. These computational validations are essential for minimizing false positives and ensuring the reproducibility of genomic findings [9]. Such integrated approaches are the cornerstone of precision oncology, enabling the design of therapeutic strategies based on the unique molecular signature of an individual's tumor [10].

Table 2. Comparative Analysis of AI Applications in Cancer Diagnostics

Diagnostic Domain	Traditional Method	AI-Enhanced Method	Advantages
Genomics	Manual variant calling and filtration; prone to human error.	AI-driven variant interpretation; automated "driver" vs. "passenger" mutation distinction.	Higher reproducibility Reduced false-positive rates in variant calling
Radiology	Visual inspection of scans; qualitative assessment.	Radiomics: Extraction of quantitative features (texture, shape) invisible to the human eye.	Non-invasive prediction of tumor phenotype Early detection of micro-metastases
Pathology	Microscopic examination; subjective grading.	Digital Pathology: Deep learning analysis of Whole Slide Images (WSI).	Standardized grading (e.g., Gleason score) Automated mitosis counting Identification of tumor-stroma ratio
Screening	Standard mammography or colonoscopy; risk of interval cancers.	AI-assisted triage and detection systems (CADe/CADx).	Increased sensitivity for early-stage lesions Reduction in unnecessary recalls (false positives)

3.1.2. AI-Driven Data Interpretation and Biomarker Discovery

The sheer volume of data generated by multi-omics studies necessitates computational assistance. AI and ML models are employed to interrogate these massive datasets to identify mutational signatures and predict clinical phenotypes [11]. These computational methods elucidate complex, non-linear relationships between multi-omic profiles that traditional statistical methods might overlook [12]. By incorporating AI into genomic pipelines, clinicians can achieve automated variant interpretation, significantly reducing the latency in clinical decision-making [13]. Moreover, these models enhance the classification accuracy of genetic variants of uncertain significance, thereby refining patient stratification for targeted therapies [14].

In the realm of biomarker discovery, identifying biological molecules that indicate disease state or therapeutic response is paramount [15]. Advanced statistical and AI-driven techniques facilitate the prioritization of potential biomarkers by correlating high-dimensional biological data with clinical outcomes [16]. Rigorous validation of these biomarkers against independent datasets is required to establish clinical relevance [17]. Once validated, these biomarkers serve as critical tools for early detection and the planning of personalized therapeutic interventions [18, 19].

3.1.3. Tumor Subtyping and Classification

Traditional histopathology relies largely on morphological assessment to classify tumors; however, molecular subtyping offers a more granular classification based on upstream genetic and transcriptomic differences [20]. AI models integrate data from transcriptomics, Next-Generation Sequencing (NGS), and epigenetic profiling to assess tumor heterogeneity with greater precision than histological methods alone [21]. Machine learning algorithms analyze this complexity to discover novel tumor subtypes and predict attributes such as tissue of origin or potential for metastasis [22]. This improved diagnostic accuracy directly facilitates the selection of targeted treatment approaches, linking genotypic characteristics to predicted therapeutic responses [23, 24].

3.2. Medical Imaging and Radiomics

3.2.1. Deep Learning in Diagnostic Imaging

AI has significantly impacted radiology, particularly in the analysis of Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and Positron Emission Tomography (PET) scans. Deep learning networks, specifically Convolutional Neural Networks (CNNs), are engineered to autonomously recognize imaging anomalies, such as minute lesions or pulmonary nodules, that may elude human detection [25]. These technologies function as a second reader, aiding radiologists in reducing interpretation errors and accelerating the diagnostic workflow. For instance, AI-driven segmentation tools can automatically delineate tumor boundaries in MRI sequences, a task that is labor-intensive and subject to inter-observer variability when performed manually.

3.2.2. Radiomics

Radiomics are a transformative approach wherein medical images are treated as mineable data rather than simple visual representations. This process involves the extraction of high-dimensional quantitative features such as texture, shape, and intensity histograms using advanced algorithms [26]. These features often correlate with underlying biological characteristics, including tumor heterogeneity and microenvironment status. Radiomic models can serve as non-invasive prognostic tools, predicting a tumor's response to chemotherapy or radiation therapy prior to treatment initiation [27]



Figure 2. Radiomics and Digital Pathology

3.3. Digital Pathology

The digitization of pathological slides has enabled the application of AI to histopathological analysis. Deep learning systems can process high-resolution Whole Slide Images (WSI) to distinguish malignant tissue from benign stroma, classify cancer subtypes, and quantify biomarker expression levels [28]. CNNs have demonstrated high proficiency in identifying metastatic cells in lymph node

biopsies and quantifying mitotic counts, tasks that are critical for staging and grading but tedious for pathologists. This automation not only increases efficiency but also reduces diagnostic subjectivity.

3.4. Early Detection and Screening

AI-powered screening systems are becoming essential components of preventative oncology. AI enhances the sensitivity of early detection protocols by recognizing subtle patterns in screening examinations. Notable successes have been observed in mammography for early-stage breast cancer detection and in colonoscopy for the identification of adenomatous polyps [29]. Recent studies indicate that AI models can match or even exceed the performance of radiologists in screening mammography, suggesting a future where AI facilitates population-level screening with higher accuracy and lower recall rates.

4. Therapeutic Implications of Artificial Intelligence

4.1. Radiotherapy Planning and Optimization

Radiotherapy is undergoing a technological evolution driven by AI, particularly in the domains of target definition and dose optimization. Deep learning systems facilitate the automated contouring of tumors and organs-at-risk (OARs), significantly reducing planning time and inter-observer variability [30]. Furthermore, machine learning models utilize historical patient data and anatomical features to predict optimal dose distributions, generating fluence maps that maximize tumor control while sparing healthy tissue [31]. AI also enables adaptive radiotherapy, allowing for real-time modification of treatment plans in response to changes in tumor volume or patient anatomy during the course of fractionation [32].

4.2. Systemic Therapy and Precision Medicine

The fusion of molecular profiling with AI has catalyzed the development of personalized chemotherapy regimens. Preclinical models utilizing machine learning can predict drug efficacy and potential toxicities by analyzing genomic, proteomic, and clinical variables [33]. Clinical decision support systems allow for the dynamic adjustment of chemotherapy agents in real-time, tailoring dosages based on biomarker feedback to optimize the therapeutic index [34]. Platforms such as CURATE exemplify this approach, utilizing AI to recommend patient-specific dosages that balance efficacy with safety profiles [35].

4.3. Surgical Oncology and Robotics

In surgical oncology, AI enhances precision through robotic-assisted systems and improved intraoperative navigation. Pre-operative AI models analyze multimodal imaging to create 3D reconstructions that delineate tumor margins and proximity to critical vascular or neural structures [36]. During procedures, robotic systems like the da Vinci Surgical System utilize AI-augmented control mechanisms to filter hand tremors and scale movements, facilitating minimally invasive surgeries with reduced complication rates [37]. Moreover, the integration of computer vision with augmented reality provides surgeons with real-time visualization of subsurface anatomy, thereby increasing the safety and radicality of resections [38].

Table 3. AI-Driven Optimizations in Cancer Therapy

Therapeutic Modality	Specific AI Application	Role/Function	Impact on Patient Care
Radiotherapy	Automated Contouring (Deep Learning)	Auto-segmentation of Gross Tumor Volume (GTV) and Organs-at-Risk (OAR).	Reduces planning time from hours to minutes Minimizes inter-observer variability
Chemotherapy	Drug Response Prediction	Integration of multi-omics data to predict sensitivity to specific agents.	Prevents administration of ineffective toxic drugs Facilitates personalized dosing (e.g., CURATE platform)
Surgery	Computer Vision & Robotics	Intraoperative navigation and 3D reconstruction of tumor margins.	Enhanced precision in tumor resection Reduced risk of damage to critical nerves/vessels
Immunotherapy	Neoantigen Prediction	Identification of tumor-specific antigens for vaccine development.	Accelerates development of personalized cancer vaccines Predicts response to checkpoint inhibitors

5. Patient Management and Clinical Operations

5.1. Remote Monitoring and Symptom Management

The advent of digital health platforms has revolutionized post-treatment care and surveillance. Remote Patient Monitoring (RPM) leverages wearable sensors and mobile health (mHealth) technologies to continuously assess physiological parameters such as heart rate, oxygen saturation, and activity levels outside the clinical setting [39, 40]. AI algorithms analyze these continuous data streams to detect early signs of clinical deterioration or treatment-related toxicities. This proactive approach allows for timely interventions before complications escalate, thereby improving treatment adherence and quality of life [41, 42]. However, the successful implementation of RPM requires robust infrastructure and strict adherence to data privacy protocols [43].



Figure 3. AI-Enabled Remote Patient Monitoring Loop

5.2. Predictive Modeling for Treatment Response

Predicting patient response to specific therapies and the likelihood of relapse is central to individualized care [44]. AI models trained on multi-omics and longitudinal clinical data can identify reliable signals that inform treatment selection [45, 46]. These predictive analytics help minimize exposure to ineffective therapies and their associated toxicities [47]. For example, ML classifiers have been developed to stratify patients with lung cancer or breast cancer based on mutation profiles (e.g., EGFR, HER2), guiding the administration of targeted therapies [48].

Table 4. Transformation of Clinical Trial Operations

Operational Aspect	Conventional Methods	AI-Enabled Method
Patient Identification	Manual review of patient charts by research coordinators.	NLP algorithms scan EHRs to match phenotypes with inclusion/exclusion criteria.
Matching Speed	Slow, labor-intensive; often misses eligible patients.	Real-time automated alerts for potential candidates.
Eligibility Criteria	Often rigid and broad.	Precision matching based on specific genomic alterations (e.g., *EGFR* mutations).
Recruitment Rate	Low (<5% of adult cancer patients enroll).	Significantly increased enrollment, particularly for rare cancers.
Data Quality	Manual data entry prone to transcription errors.	Automated data capture from source documents.

5.3. Clinical Trial Matching

The recruitment of patients for clinical trials is often hindered by complex eligibility criteria and unstructured patient data. AI and NLP tools streamline this process by automatically screening electronic health records against trial protocols to identify suitable candidates [49]. Genomic-driven matching platforms further refine this process by aligning patients with trials targeting their specific

molecular alterations [50]. Automated matching systems significantly accelerate recruitment timelines and improve access to experimental therapies, particularly for patients with rare or treatment-refractory malignancies [51].

6. Drug Discovery and Development

The traditional oncology drug discovery pipeline is historically characterized by exorbitant costs, protracted timelines, and high attrition rates, with successful development often exceeding a decade. Artificial Intelligence is fundamentally disrupting this paradigm by introducing computational efficiencies across every stage of the pharmaceutical value chain.

6.1. Target Identification and Validation

The initial phase of drug discovery involves identifying biological targets such as proteins, genes, or RNA molecules that are implicated in cancer progression. AI algorithms, particularly those utilizing knowledge graphs and network biology, analyze vast repositories of biomedical literature, genomic databases, and protein interaction networks to discover novel therapeutic targets [52]. Deep learning models can predict protein structure and function (e.g., AlphaFold), allowing researchers to validate whether a specific protein is "druggable" before physical experimentation begins. This computational prioritization significantly reduces the time spent investigating non-viable targets.

Table 5. Impact of AI on the Pharmaceutical Value Chain

Development Phase	Challenges	AI Solution	Example
Target Discovery	High failure rate due to poor target validation.	Knowledge Graphs: Integrate literature and omics data to identify novel targets.	Network Biology analysis
Lead Optimization	"Trial and error" chemical synthesis; slow iterative cycles.	Generative Models: *De novo* design of molecules with optimized binding affinity.	GANs, Reinforcement Learning
Preclinical Safety	Late-stage failure due to unforeseen toxicity.	ADMET Prediction: *In silico* forecasting of toxicity and metabolism.	QSAR Modeling
Drug Repurposing	Serendipitous discovery.	Transcriptomic Matching: Systematic identification of non-cancer drugs reversing tumor signatures.	Connectivity Map (CMap) analysis
Clinical Development	High cost, long timelines (>10 years).	Predictive Modeling: Simulating trial outcomes and optimizing patient selection.	Digital Twins, Synthetic Control Arms

6.2. De Novo Drug Design and Lead Optimization

Once a target is validated, AI facilitates the design of novel molecules with high binding affinity. Generative Adversarial Networks (GANs) and Reinforcement Learning (RL) models are employed to generate molecular structures *de novo*, exploring chemical spaces far larger than traditional libraries. Quantitative Structure-Activity Relationship (QSAR) models then predict the biological activity of these compounds, optimizing them for potency and selectivity. This "inverse design" approach allows for the creation of lead compounds that are structurally optimized for their intended targets much faster than traditional high-throughput screening [53].

6.3. Drug Repurposing

Drug repurposing, or repositioning, involves identifying new therapeutic uses for existing, approved drugs. This strategy offers a faster route to clinical application as the safety profiles of these agents are already established. AI-driven network pharmacology platforms integrate transcriptomic signatures of cancer cell lines with drug-response databases (e.g., CMap, LINCS) to identify non-oncology drugs that can reverse cancer-specific gene expression signatures [54]. This approach has successfully identified candidates such as metformin and certain beta-blockers for potential adjuvant cancer therapies.

6.4. Toxicity Prediction and Safety Profiling

A major cause of clinical trial failure is unforeseen toxicity. AI models, trained on large datasets of chemical properties and historical clinical trial data, can predict ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties with high accuracy [53]. By forecasting potential adverse events, hepatotoxicity, or cardiotoxicity in the preclinical phase, AI enables researchers to filter out unsafe compounds early, thereby improving the success rate of subsequent clinical trials and ensuring patient safety



Figure 4. AI-Accelerated Drug Discovery Pipeline.

7. Conclusion

Artificial intelligence is rapidly redefining the standards of oncological practice by providing the computational power necessary to interpret complex biomedical data. From enhancing diagnostic precision through radiomics and genomic analysis to optimizing therapeutic interventions in surgery and radiotherapy, AI is integral to the realization of precision medicine. The technology's ability to facilitate dynamic patient monitoring and accelerate drug discovery further underscores its transformative potential. However, the widespread clinical adoption of AI requires addressing significant challenges, including the need for robust validation studies, the assurance of patient data privacy, and the mitigation of algorithmic bias.

References

[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

[2] Esteva A, Robicquet A, Ramsundar B, Kuleshov V, DePristo M, Chou K, et al. A guide to deep learning in healthcare. Nat Med. 2019;25(1):24–9.

[3] Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44–56.

[4] Johnson KW, Torres Soto J, Glicksberg BS, Shameer K, Miotto R, Ali M, et al. Artificial intelligence in cardiology. J Am Coll Cardiol. 2018;71(23):2668–79.

[5] Rajkomar A, Dean J, Kohane I. Machine learning in medicine. N Engl J Med. 2019;380(14):1347–58.

[6] Garraway LA, Lander ES. Lessons from the cancer genome. Cell. 2013;153(1):17–37.

[7] Mardis ER. Next-generation sequencing platforms. Annu Rev Anal Chem (Palo Alto Calif). 2013;6:287–303.

[8] Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127):1546–58.

[9] Harismendy O, Frazer KA. Method for comparing large-scale genomic data sets. Genome Res. 2009;19(12):2167–73.

[10] Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793–5.

[11] Kourou K, Exarchos TP, Exarchos KP, Karamouzis MV, Fotiadis DI. Machine learning applications in cancer prognosis and prediction. Comput Struct Biotechnol J. 2015;13:8–17.

[12] Chen R, Snyder M. Promise of personalized omics to precision medicine. Wiley Interdiscip Rev Syst Biol Med. 2013;5(1):73–82.

[13] Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer. J Mol Diagn. 2017;19(1):4–23.

[14] Libbrecht MW, Noble WS. Machine learning applications in genetics and genomics. Nat Rev Genet. 2015;16(6):321–32.

[15] Henry NL, Hayes DF. Cancer biomarkers. Mol Oncol. 2012;6(2):140–6.

[16] Mertins P, Mani DR, Ruggles KV, Gillette MA, Clauser KR, Wang P, et al. Proteogenomics connects somatic mutations to signaling in breast cancer. Nature. 2016;534(7605):55–62.

[17] Xu Y, Goodacre R. On splitting training and validation set: A comparative study of cross-validation, bootstrap and systematic sampling for estimating the generalization performance of supervised learning. J Anal Test. 2018;2(3):249–62.

[18] Poste G. Bring on the biomarkers. Nature. 2011;469(7329):156–7.

[19] Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14(9):531–48.

[20] Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell. 2014;158(4):929–44.

[21] Cancer Genome Atlas Research Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70.

[22] Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350–6.

[23] Jiao Y, Killela PJ, Reitman ZJ, Rasheed BA, Heaphy CM, de Wilde RF, et al. Frequent ATRX, CIC, and FUBP1 mutations refine the classification of malignant gliomas. Oncotarget. 2012;3(7):709–22.

[24] Shen R, Olshen AB, Ladanyi M. Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis. Bioinformatics. 2009;25(22):2906–12.

[25] Ardila D, Kiraly AP, Bharadwaj S, Choi B, Reicher JJ, Peng L, et al. End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography. Nat Med. 2019;25(6):954–61.

[26] Gillies RJ, Kinahan PE, Hricak H. Radiomics: Images are more than pictures, they are data. Radiology. 2016;278(2):563–77.

[27] Aerts HJWL, Velazquez ER, Leijenaar RTH, Parmar C, Grossmann P, Carvalho S, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014;5:4006.

[28] Cireşan DC, Giusti A, Gambardella LM, Schmidhuber J. Mitosis detection in breast cancer histology images with deep neural networks. Med Image Comput Comput Assist Interv. 2013;16(Pt 2):411–8.

[29] McKinney SM, Sieniek M, Godbole V, Godwin J, Antropova N, Ashrafian H, et al. International evaluation of an AI system for breast cancer screening. Nature. 2020;577(7788):89–94.

[30] Men K, Dai J, Li Y. Automatic segmentation of head and neck organs at risk using convolutional neural networks. Med Phys. 2017;44(3):1070–80.

[31] Nguyen D, Long T, Jia X, Lu W, Gu X, Iqbal Z, et al. A feasibility study for predicting optimal radiation therapy dose distributions of prostate cancer patients from patient anatomy using deep learning. Sci Rep. 2019;9(1):1076.

[32] Berbeco RI, Ngwa W, Makrigiorgos GM. Stereotactic radiotherapy and radiogenomics: Emerging technologies for precision cancer treatment. Expert Rev Precis Med Drug Dev. 2017;2(2):85–95.

[33] Adam G, Rampášek L, Safikhani Z, Smirnov P, Haibe-Kains B, Goldenberg A. Machine learning approaches to drug response prediction: Challenges and recent progress. NPJ Precis Oncol. 2020;4(1):19.

[34] Lee SI, Celik S, Logsdon BA, Lundberg SM, Martins TJ, Oehler VG, et al. A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia. Nat Commun. 2018;9(1):42.

[35] Kaushik AC, Wang X. Deep learning in modern healthcare: Applications, challenges, and future opportunities. IEEE Access. 2020;8:209690–708.

[36] Hashimoto DA, Rosman G, Rus D, Meireles OR. Artificial intelligence in surgery: Promises and perils. Ann Surg. 2018;268(1):70–6.

[37] Li Z, Zhang H, Zhang J, Chen P, Huang Q. Robot-assisted precision surgery: From concept to clinical applications. Int J Med Robot. 2020;16(4):e2105.

[38] Marescaux J, Rubino F. Augmented reality-assisted surgery: A new era of surgical teaching and precision surgery. Surg Endosc. 2004;18(9):1412–4.

[39] Steinhubl SR, Muse ED, Topol EJ. Can mobile health technologies transform health care? JAMA. 2013;310(22):2395–6.

[40] Piwek L, Ellis DA, Andrews S, Joinson A. The rise of consumer health wearables: Promises and barriers. PLoS Med. 2016;13(2):e1001953.

[41] Patel MS, Asch DA, Volpp KG. Wearable devices as facilitators, not drivers, of health behavior change. JAMA. 2015;313(5):459–60.

[42] Coravos A, Khozin S, Mandl KD. Developing and adopting safe and effective digital biomarkers to improve patient outcomes. NPJ Digit Med. 2019;2(1):14.

[43] Price WN, Cohen IG. Privacy in the age of medical big data. Nat Med. 2019;25(1):37–43.

[44] Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. N Engl J Med. 2018;378(2):113–25.

[45] Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92.

[46] Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. Genome Biol. 2017;18(1):83.

[47] Joyner MJ, Paneth N. Seven questions for personalized medicine. JAMA. 2015;314(10):999–1000.

[48] Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–39.

[49] Shivade C, Raghavan P, Fosler-Lussier E, Embi PJ, Elhadad N, Johnson SB, et al. A review of approaches to identifying patient phenotype cohorts using electronic health records. J Am Med Inform Assoc. 2014;21(2):221–30.

[50] Schwaederle M, Zhao M, Lee JJ, Eggermont AM, Schilsky RL, Mendelsohn J, et al. Impact of precision medicine in diverse cancers: A meta-analysis of phase II clinical trials. J Clin Oncol. 2015;33(32):3817–25.

[51] Cruz Rivera S, Liu X, Chan AW, Denniston AK, Calvert MJ, Glasziou P, et al. Can artificial intelligence streamline patient recruitment to clinical trials? Lancet Digit Health. 2020;2(10):e521–3.

[52] Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019;18(6):463–77.

[53] Ekins S, Puhl AC, Zorn KM, Lane TR, Russo DP, Klein JJ, et al. Exploiting machine learning for end-to-end drug discovery and development. Nat Mater. 2019;18(5):435–41.

[54] Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: Progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18(1):41–58.